Novo Nordisk's dosing in CagriSema obesity drug trial puzzles investors December 20, 2024 The U.S. Food and Drug Administration has approved Ionis Pharmaceuticals' drug to treat a rare genetic ...
There’s a saying that in a big city you are never more than six feet away from a rat. It’s an urban myth, but scientists are warning cities across the globe are becoming far rattier ...
WASHINGTON — (AP) — Rat infestation in many world cities appears to be soaring, especially in Washington, and a new study blames warming temperatures, urbanization and other human actions.
Copyright 2025 The Associated Press. All Rights Reserved. A rat leaves its burrow at a park in New York City on Sept. 17, 2015. ( AP Photo/Mary Altaffer, File) A rat ...
The trial showed that patients treated with CagriSema exhibited weight loss of 22.7% after 68 weeks, well short of Novo's targeted expectation of at least 25% weight loss. The press release ...
The stock is down about 40% from a record in June, with a chunk of the drop coming after disappointing results for a separate drug called CagriSema in December. The experimental CagriSema shot ...
JABALIA, Gaza (Reuters) - The rats and dogs scavenging amid the ruins of her neighborhood in northern Gaza make Manal Al-Harsh's return to her wrecked home even more miserable. Despite the respite ...
In the first study of its kind, scientists found a correlation between climate change and a rise in urban rat populations. A rat scurries across West Broadway in New York City. A study looking at ...
The stock is down about 40% from a record in June, with a chunk of the drop coming after disappointing results for a separate drug called CagriSema in December. The experimental CagriSema shot missed ...
LONDON, Jan 30 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab will begin a late-stage trial of its experimental next-generation obesity drug CagriSema on Feb. 10 to test its long-term efficacy ...
The Novo Nordisk class action lawsuit further alleges that on December 20, 2024, defendants published headline results from their REDEFINE-1 CagriSema obesity trial, disclosing that “[t]he ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results